A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Stopped The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.
Conditions
- C3 Glomerulonephritis
- C3 Glomerulopathy
- Immune Complex Membranoproliferative Glomerulonephritis
- IC-MPGN
- Dense Deposit Disease
Interventions
Sponsor
Alexion Pharmaceuticals, Inc.